[
    [
        {
            "time": "2018-12-31",
            "original_text": "Eli Lilly and Co (LLY) Files 10-K for the Fiscal Year Ended on December 31, 2018",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "10-K",
                    "Fiscal Year"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly and Co (LLY) Files 10-K for the Fiscal Year Ended on December 31, 2018",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 4,
                "Source_Recency": 2
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why",
            "features": {
                "keywords": [
                    "Merck",
                    "Stock Up",
                    "50%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo",
            "features": {
                "keywords": [
                    "Bayer",
                    "Vitrakvi",
                    "Lilly",
                    "Loxo"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?",
            "features": {
                "keywords": [
                    "Teva",
                    "Growth Drivers",
                    "2019"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "Pfizer-Lilly drug shown to help reduce back pain in late-stage trial",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Lilly",
                    "drug",
                    "back pain",
                    "trial"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pfizer-Lilly drug shown to help reduce back pain in late-stage trial",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "Higher dose of Pfizer-Lilly drug helps reduce back pain in study",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Lilly",
                    "drug",
                    "higher dose",
                    "back pain",
                    "study"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Higher dose of Pfizer-Lilly drug helps reduce back pain in study",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-01-01",
            "original_text": "Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Lilly",
                    "Tanezumab",
                    "Phase 3",
                    "Chronic Low Back Pain"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]